LMNL Archives - BioTuesdays

Markets

Leede Jones Gable starts Liminal BioSciences at hold; PT $4

Leede Jones Gable initiated coverage of Liminal BioSciences (NASDAQ:LMNL) with a “hold” rating and $4 price target. The stock closed at $4.20 on Dec. 15. Liminal is a plasma products and anti-fibrotic small molecule...

December 16, 2020

Developments

Liminal BioSciences acquires Fairhaven Pharmaceuticals

Liminal BioSciences (NASDAQ, TSX:LMNL) acquired closely-held Fairhaven Pharmaceuticals for $8-million (Canadian) in common shares. Fairhaven’s assets include a preclinical research program of small molecule...

July 17, 2020

Developments

Luminal BioSciences provides guidance on milestones; begins collecting plasma from COVID-19 recovered donors

Liminal BioSciences (NASDAQ, TSX:LMNL) provided a guidance update on the timing of certain expected key milestones for 2020. The company withdrew guidance in May because of the COVID-19 pandemic. In a statement, Kenneth...

July 1, 2020

Feature

Liminal BioSciences making headway in strategic transformation

Liminal BioSciences (NASDAQ, TSX:LMNL) is undergoing a significant strategic transformation to simplify its operations, achieve financial stability and focus R&D on small molecule therapeutics. “This is a refresh of...

January 21, 2020

Developments

Liminal presents new preclinical data for PBI-4050 on PAH

Liminal BioSciences (NASDAQ:LMNL; TSX:LMNL) presented two scientific posters with new preclinical data for its PBI-4050 drug candidate and the treatment of pulmonary arterial hypertension (PAH) at the American Heart...

November 19, 2019

Markets

Liminal BioSciences to begin trading on NASDAQ

Common shares of Liminal BioSciences (TSX:LMNL; OTCQX:PFSCF) were approved for trading on the Nasdaq Global Market, effective Nov. 18, under the ticker symbol, LMNL. The shares will continue to trade on the Toronto...

November 15, 2019

Executive Moves

Liminal BioSciences names Moira Daniels to head regulatory affairs, quality assurance

Liminal BioSciences (TSX:LMNL; OTCQX:LMNL) appointed Moira Daniels as the new head of regulatory affairs and quality assurance based at the company’s offices in Cambridge, UK. “Moira brings many years of global...

November 13, 2019

Developments

Liminal BioSciences presents new preclinical data at ASN Kidney Week

Liminal BioSciences (TSX:LMNL; OTCQX:PFSCF) and its collaborators presented new preclinical findings on a novel therapeutic approach to the treatment of inflammatory and fibrosis-related kidney diseases at the American...

November 11, 2019

Developments

Liminal BioSciences to sell bioseparations division to KKR

Liminal BioSciences (TSX:LMNL; OTCQX:PFSCF) signed a binding share purchase agreement for the proposed saleof its Isle of Man-based bioseparations business operated through subsidiary Prometic Bioseparations (PBL) to...

November 4, 2019

Developments

Liminal BioSciences to present PAH data at AHA meeting

Liminal BioSciences (TSX:LMNL; OTCQX:PFSCF) plans to present two scientific posters with new preclinical development in the treatment of pulmonary arterial hypertension (PAH) at the American Heart Association annual...

October 29, 2019

Tag - LMNL

Leede Jones Gable starts Liminal BioSciences at hold; PT $4

Liminal BioSciences acquires Fairhaven Pharmaceuticals

Luminal BioSciences provides guidance on milestones; begins collecting plasma from COVID-19 recovered donors

Liminal BioSciences making headway in strategic transformation

Liminal presents new preclinical data for PBI-4050 on PAH

Liminal BioSciences to begin trading on NASDAQ

Liminal BioSciences names Moira Daniels to head regulatory affairs, quality assurance

Liminal BioSciences presents new preclinical data at ASN Kidney Week

Liminal BioSciences to sell bioseparations division to KKR

Liminal BioSciences to present PAH data at AHA meeting

General

More